PET Imaging Validates Cholesterol Drug for HER2 Cancer Therapy Enhancement

Combining a single dose of HER2-targeted antibody-drug conjugate therapy with lovastatin, monitored by immuno-PET scans, demonstrates the potential to achieve therapeutic efficacy similar to multiple doses while minimizing side effects in HER2-positive cancer patients.